Sage Journals: Discover world-class research

Abstract

Aims

Exposure to airborne particulate matter has been consistently associated with early death and increased morbidity, particularly raising the risk of cardiovascular disease. Obesity, one of the leading cardiovascular disease risk factors, increases susceptibility to the adverse effects of particulate matter exposure. Proprotein convertase subtilisin/kexin type 9 has been related to a large number of cardiovascular risk factors, e.g. atherogenic lipoproteins, arterial stiffness and platelet activation. Thus, the present study was aimed at evaluating, in a series of obese individuals, the effects of particulate matter less than 10 µm in diameter (PM₁₀) on proprotein convertase subtilisin/kexin type 9 circulating levels.

Methods and results

In 500 obese subjects, participating in the cross-sectional Susceptibility to Particle Health Effects, miRNAs and Exosomes (SPHERE) study, we evaluated the effects of long- and short-term PM₁₀ exposure on circulating proprotein convertase subtilisin/kexin type 9 levels. In the studied individuals (body mass index: 33.3 ± 5.2 kg/m²) with an annual average PM₁₀ exposure of 40.12 ± 4.71 µg/m³, proprotein convertase subtilisin/kexin type 9 levels were 248.7 ± 78.6 ng/mL. In univariate analysis, PM₁₀ exposure (annual average) was associated with proprotein convertase subtilisin/kexin type 9 levels (β=1.83, standard error = 0.75, p = 0.014). Interestingly, in a multivariable linear regression model, this association was observed only for carriers of lower concentrations of interferon-γ, whereas it was lost in the presence of higher interferon-γ levels. Proprotein convertase subtilisin/kexin type 9 levels were positively associated with the Framingham Risk Score, which was raised by 15.8% for each 100 ng/ml rise of proprotein convertase subtilisin/kexin type 9.

Conclusions

In obese individuals, more sensitive to the damaging effects of environmental air pollution, PM₁₀ exposure positively associates with proprotein convertase subtilisin/kexin type 9 plasma levels especially in those with low levels of interferon-γ.

Keywords

Air pollution Framingham Risk Score particular matter proprotein convertase subtilisin/kexin type 9

Get full access to this article

View all access options for this article.

References

Mendis

. Global progress in prevention of cardiovascular disease. Cardiovasc Diagn Ther 2017; 7: S32–S38.

Brauer

Freedman

Frostad

et al.

Ambient air pollution exposure estimation for the global burden of disease 2013. Environ Sci Technol 2016; 50: 79–88.

Landrigan

Fuller

Acosta

NJR

et al.

The Lancet Commission on pollution and health. Lancet 2018; 391: 462–512.

Mannucci

. Air pollution levels and cardiovascular health: Low is not enough. Eur J Prev Cardiol 2017; 24: 1851–1853.

Jin

et al.

Impact of particulate air pollution on cardiovascular health. Curr Allergy Asthma Rep 2018; 18: 15–15.

Newby

Mannucci

Tell

et al.

Expert position paper on air pollution and cardiovascular disease. Eur Heart J 2015; 36: 83–93b.

Brook

Rajagopalan

Pope

3rd et al.

Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010; 121: 2331–2378.

Bastien

Poirier

Lemieux

et al.

Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014; 56: 369–381.

Weichenthal

Hoppin

Reeves

. Obesity and the cardiovascular health effects of fine particulate air pollution. Obesity 2014; 22: 1580–1589.

10.

Gualtieri

Ovrevik

Holme

et al.

Differences in cytotoxicity versus pro-inflammatory potency of different PM fractions in human epithelial lung cells. Toxicol In Vitro 2010; 24: 29–39.

11.

Hetland

Cassee

Refsnes

et al.

Release of inflammatory cytokines, cell toxicity and apoptosis in epithelial lung cells after exposure to ambient air particles of different size fractions. Toxicol In Vitro 2004; 18: 203–212.

12.

Baccarelli

Bollati

. Epigenetics and environmental chemicals. Curr Opin Pediatr 2009; 21: 243–251.

13.

Abifadel

Varret

Rabes

et al.

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154–156.

14.

Lakoski

Lagace

Cohen

et al.

Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 94: 2537–2543.

15.

Dijk

Le May

Cariou

. Beyond LDL: What role for PCSK9 in triglyceride-rich lipoprotein metabolism? Trends Endocrinol Metab 2018; 29: 420–434.

16.

Camera

Rossetti

Barbieri

et al.

PCSK9 as a positive modulator of platelet activation. J Am Coll Cardiol 2018; 71: 952–954.

17.

Cohen

Boerwinkle

Mosley

Jr et al.

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–1272.

18.

Vlachopoulos

Terentes-Printzios

Georgiopoulos

et al.

Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis 2016; 252: 50–60.

19.

Qiu

Zhou

et al.

High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies. Medicine 2017; 96: e8848–e8848.

20.

Pott

Schlegel

Teren

et al.

Genetic regulation of PCSK9 (proprotein convertase subtilisin/kexin type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes. Circ Genom Precis Med 2018; 11: e001992–e001992.

21.

Bollati

Iodice

Favero

et al.

Susceptibility to particle health effects, miRNA and exosomes: Rationale and study protocol of the SPHERE study. BMC Public Health 2014; 14: 1137–1137.

22.

Pergoli

Cantone

Favero

et al.

Extracellular vesicle-packaged miRNA release after short-term exposure to particulate matter is associated with increased coagulation. Part Fibre Toxicol 2017; 14: 32–32.

23.

Persson

Cao

Stahle

et al.

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010; 30: 2666–2672.

24.

Cicoira

. Ambient air pollution as a new risk factor for cardiovascular diseases: Time to take action. Eur J Prev Cardiol 2018; 25: 816–817.

25.

Brook

Franklin

Cascio

et al.

Air pollution and cardiovascular disease: A statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation 2004; 109: 2655–2671.

26.

Hadley

Baumgartner

Vedanthan

. Developing a clinical approach to air pollution and cardiovascular health. Circulation 2018; 137: 725–742.

27.

Munzel

Sorensen

Gori

et al.

Environmental stressors and cardio-metabolic disease: Part II-mechanistic insights. Eur Heart J 2017; 38: 557–564.

28.

Munzel

Gori

Babisch

et al.

Cardiovascular effects of environmental noise exposure. Eur Heart J 2014; 35: 829–836.

29.

Ferri

Tibolla

Pirillo

et al.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012; 220: 381–386.

30.

Ferri

Marchiano

Tibolla

et al.

PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis 2016; 253: 214–224.

31.

Werner

Hoffmann

Winkler

et al.

Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol 2014; 62: 94–102.

32.

Zhu

Anderson

Sikdar

et al.

Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol 2015; 35: 2254–2259.

33.

Ridker

Rifai

Bradwin

et al.

Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J 2016; 37: 554–560.

34.

Gencer

Montecucco

Nanchen

et al.

Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J 2016; 37: 546–553.

35.

Leander

Malarstig

Van’t Hooft

et al.

Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation 2016; 133: 1230–1239.

36.

Liberale

Carbone

Bertolotto

et al.

Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. Int J Cardiol 2018; 263: 138–141.

37.

Rao

Lindholm

Rivas

et al.

Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke. Circ Genom Precis Med 2018; 11: e002162–e002162.

38.

Ruscica

Ricci

Macchi

et al.

Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem 2016; 291: 3508–3519.

39.

Fernandes

Ritti-Dias

Balagopal

et al.

Self-initiated physical activity is associated with high sensitivity C-reactive protein: A longitudinal study in 5,030 adults. Atherosclerosis 2018; 273: 131–135.

40.

Tunon

Back

Badimon

et al.

Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. Eur J Prev Cardiol 2018; 25: 948–955.

41.

Ricci

Ruscica

Camera

et al.

PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep 2018; 8: 2267–2267.

42.

Tobaldini

Bollati

Prado

et al.

Acute particulate matter affects cardiovascular autonomic modulation and IFN-gamma methylation in healthy volunteers. Environ Res 2018; 161: 97–103.

43.

Baass

Dubuc

Tremblay

et al.

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009; 55: 1637–1645.

44.

Ruscica

Ferri

Fogacci

et al.

Circulating levels of proprotein convertase subtilisin/kexin type 9 and arterial stiffness in a large population sample: Data from the Brisighella Heart Study. J Am Heart Assoc 2017; 6: e005764–e005764.

45.

Ruscica

Simonelli

Botta

et al.

Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochim Biophys Acta 2018; 1863: 991–997.

46.

Wilson

D’Agostino

Levy

et al.

Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

47.

D’Agostino

Sr Vasan

Pencina

et al.

General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743–753.

48.

Menotti

Puddu

Lanti

. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21: 365–370.

49.

Ferrario

Chiodini

Chambless

et al.

Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 2005; 34: 413–421.

50.

La Torre

Palmeri

Pagano

et al.

Evaluation of cardiovascular risk profile: A comparative analysis between CUORE algorithm and the Framingham risk scores. Eur Rev Med Pharmacol Sci 2018; 22: 2398–2404.

51.

Zanni

Stone

Toribio

et al.

Proprotein convertase subtilisin/kexin 9 levels in relation to systemic immune activation and subclinical coronary plaque in HIV. Open Forum Infect Dis 2017; 4: ofx227–ofx227.

52.

Bigi

Ghermandi

. Long-term trend and variability of atmospheric PM10 concentration in the Po Valley. Atmos Chem Phys 2014; 14: 4895–4907.

53.

Asikainen

Carrer

Kephalopoulos

et al.

Reducing burden of disease from residential indoor air exposures in Europe (HEALTHVENT project). Environ Health 2016; 15: S35–S35.

54.

Vidale

Campana

. Ambient air pollution and cardiovascular diseases: From bench to bedside. Eur J Prev Cardiol 2018; 25: 818–825.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.00 MB

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals

Abstract

Aims

Methods and results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material